# The Comparative Safety and Effectiveness of Dabigatran, Versus Rivaroxaban, and Apixaban Utilized in the Department of Defense Non-Valvular Atrial Fibrillation Patient Population: A Retrospective Database Analysis

> **NCT03026556** · — · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 42534 (actual)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** Dabigatran vs. Rivaroxaban
- **DRUG:** Dabigatran vs. Apixaban

## Key facts

- **NCT ID:** NCT03026556
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-29
- **Primary completion:** 2017-08-23
- **Final completion:** 2017-08-23
- **Target enrollment:** 42534 (ACTUAL)
- **Last updated:** 2019-06-03

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03026556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03026556, "The Comparative Safety and Effectiveness of Dabigatran, Versus Rivaroxaban, and Apixaban Utilized in the Department of Defense Non-Valvular Atrial Fibrillation Patient Population: A Retrospective Database Analysis". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03026556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*